ResMed's SWOT analysis: sleep tech giant faces GLP-1 drug challenge
ResMed Inc . (NYSE:RMD; ASX:RMD), a leading player in the sleep and respiratory care market, has demonstrated strong operational performance in recent quarters. However, the company faces potential ...
This gentle form of exercise reduces your risk of sleep apnea by 10%, study says
Sleep apnea affects over 29 million Americans, with Obstructive Sleep Apnea (characterized by pauses in breathing during ...
SouthFlorida Reporter1 天
The Silent Sleep Crisis: How Sleep Solution Centers is Revolutionizing Sleep Health in Florida
While Continuous Positive Airway Pressure (CPAP) machines have long been the standard treatment, many patients find them uncomfortable or difficult to use. Fortunately, Sleep Solution Centers, a ...
HME News3 天
ResMed moves to address ‘educational gap’ on PAP devices, GLP-1s
In the wake of the U.S. Food and Drug Administration’s approval of Zepbound to treat moderate to severe obstructive sleep ...
Q2 2025 Resmed Inc Earnings Call
Welcome to the Q2 fiscal-year 2025 ResMed earnings conference call. My name is Matt and I'll be your operator for today's call. (Operator Instructions) Please note that this conference call is being ...
ResMed Inc. (NYSE:RMD) Q2 2025 Earnings Call Transcript
Q2 2025 Earnings Call Transcript January 30, 2025 ResMed Inc. beats earnings expectations. Reported EPS is $2.43, expectations were $2.32. Operator: Welcome to the Q2 Fiscal Year 2025 ResMed Earnings ...
Resmed: Hold Rating Amid Growth Deceleration and Emerging Competitive Risks
Needham analyst Michael Matson has maintained their neutral stance on RMD stock, giving a Hold rating on January 29.Invest with Confidence: ...
ResMed's Moat Is Underpinned by Switching Costs and Intangible Brand Assets
Due to its significant market share and high gross margins in a structurally growing industry, ResMed has posted an average return on invested capital, or ROIC, of 20% over the last decade. We ...
ResMed targets 59-60% gross margins and expanded global reach for AirSense 11
CEO Michael Farrell reported 10% global revenue growth, driven by demand across the sleep health, breathing health, and residential care software portfolios. Device sales, including AirSense 10 and ...
ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2025
ResMed Inc. (NYSE: RMD, ASX: RMD) today announced results for its quarter ended December 31, 2024. Revenue increased by 10% to $1.3 billion; up 10% on a constant currency basis  Gross margin improved ...
fnarena4 天
ResMed: Another Positive Quarterly Surprise?
UBS makes a similar comment, stating ResMed shares are trading at 23x FY26 earnings. Although this represents a 40% premium ...
Future Market Insights4 天
Sleep Apnea Devices Market to Reach USD 20.4 Billion by 2033 at a 9.5% of CAGR, Amid Rising ...
The global sleep apnea devices market is set to expand at a steady CAGR of 9.5%, growing from USD 8.2 billion in 2023 to USD ...